{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T20:12:31Z","timestamp":1769458351558,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1115556"],"award-info":[{"award-number":["OPP 1115556"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1115556"],"award-info":[{"award-number":["OPP1115556"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.lanwpc.2022.100484","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T16:19:21Z","timestamp":1653927561000},"page":"100484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age"],"prefix":"10.1016","volume":"24","author":[{"given":"Josefina Cadorna","family":"Carlos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-8605","authenticated-orcid":false,"given":"Birkneh Tilahun","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charissa","family":"Borja-Tabora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edison","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle C.","family":"Ylade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arijit","family":"Sil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Seon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seon-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-hwa","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hokeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoonyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-9268","authenticated-orcid":false,"given":"Zenaida Reynoso","family":"Mojares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Anh","family":"Wartel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lanwpc.2022.100484_bib0001","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.lanwpc.2022.100484_bib0002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/s12879-016-2074-1","article-title":"Geographical distribution of typhoid risk factors in low and middle income countries","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1016\/j.lanwpc.2022.100484_bib0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.lanwpc.2022.100484_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004616","article-title":"The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysis","volume":"10","author":"John","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2022.100484_bib0005","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"Journal of global health"},{"issue":"13","key":"10.1016\/j.lanwpc.2022.100484_bib0006","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197009242831306","article-title":"Typhoid fever: pathogenesis and immunologic control","volume":"283","author":"Hornick","year":"1970","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.lanwpc.2022.100484_bib0007","doi-asserted-by":"crossref","first-page":"k5322","DOI":"10.1136\/bmj.k5322","article-title":"Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities","volume":"364","author":"Parry","year":"2019","journal-title":"Bmj"},{"issue":"12","key":"10.1016\/j.lanwpc.2022.100484_bib0008","first-page":"1824","article-title":"Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease","volume":"67","author":"Jeon","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.lanwpc.2022.100484_bib0009","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2022.100484_bib0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - Recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.lanwpc.2022.100484_bib0011","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the Typhoid Conjugate Vaccine Pipeline: Current Status and Future Plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.lanwpc.2022.100484_bib0012","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.lanwpc.2022.100484_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0264-410X(95)00186-5","article-title":"Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization","volume":"14","author":"Klugman","year":"1996","journal-title":"Vaccine"},{"issue":"14-15","key":"10.1016\/j.lanwpc.2022.100484_bib0014","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0264-410X(98)00097-8","article-title":"Potential and limitations of polysaccharide vaccines in infancy","volume":"16","author":"Cadoz","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.lanwpc.2022.100484_bib0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/1040841X.2016.1249335","article-title":"Vi capsular polysaccharide: Synthesis, virulence, and application","volume":"43","author":"Hu","year":"2017","journal-title":"Crit Rev Microbiol"},{"issue":"4","key":"10.1016\/j.lanwpc.2022.100484_bib0016","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: School based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.lanwpc.2022.100484_bib0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lanwpc.2022.100484_bib0018","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.lanwpc.2022.100484_bib0019","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1093\/cid\/ciaa343","article-title":"Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?","volume":"71","author":"Steele","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"26","key":"10.1016\/j.lanwpc.2022.100484_bib0020","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.lanwpc.2022.100484_bib0021","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1016\/j.vaccine.2019.09.074","article-title":"Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report","volume":"38","author":"Capeding","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.lanwpc.2022.100484_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.lanwpc.2022.100484_bib0023","first-page":"726","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.lanwpc.2022.100484_bib0024","unstructured":"Medical Dictionary for Regulatory Activities \u2013 MedDRA. https:\/\/www.meddra.org\/. Accessed 20 September 2019."},{"issue":"1","key":"10.1016\/j.lanwpc.2022.100484_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-022-00434-8","article-title":"Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose","volume":"7","author":"Capeding","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"7","key":"10.1016\/j.lanwpc.2022.100484_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071394","article-title":"A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination","volume":"9","author":"Jones","year":"2021","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.lanwpc.2022.100484_bib0027","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2020","journal-title":"Journal of Experimental Medicine"},{"issue":"11","key":"10.1016\/j.lanwpc.2022.100484_bib0028","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate - a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"17","key":"10.1016\/j.lanwpc.2022.100484_bib0029","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"The New England journal of medicine"},{"issue":"7","key":"10.1016\/j.lanwpc.2022.100484_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13312-020-1890-y","article-title":"Immunogenicity and Safety of Typhoid Conjugate Vaccine in Healthy Indian Subjects: A Randomized, Active-controlled, Comparative Clinical Trial","volume":"57","author":"Kundu","year":"2020","journal-title":"Indian Pediatr"},{"issue":"23","key":"10.1016\/j.lanwpc.2022.100484_bib0031","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"The New England journal of medicine"},{"issue":"2","key":"10.1016\/j.lanwpc.2022.100484_bib0032","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606522000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606522000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T08:28:47Z","timestamp":1722155327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606522000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"alternative-id":["S2666606522000992"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100484","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100484"}}